title: Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?
authors.affiliation: sanmiguel@unav.es.
authors.forename: Jesús F
authors.initials: JF
authors.lastname: San Miguel
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications* / Q000628:therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000209:etiology* / Q000517:prevention & control*
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib